APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antisense and RNAi Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Antisense and RNAi Therapeutics Market Analysis and Forecast 2026-2032

21 December 2025190 pages

Choose your research edition.

Industry ResearchAntisense and RNAi Therapeutics Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Antisense and RNAi Therapeutics Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Antisense and RNAi Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antisense and RNAi Therapeutics Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Antisense and RNAi Therapeutics Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Antisense and RNAi Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Antisense and RNAi Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Antisense and RNAi Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Antisense and RNAi Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Antisense and RNAi Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Antisense and RNAi Therapeutics include Roche, Tekmira Pharmaceuticals, Sirnaomics, Silence Therapeutics, Santaris, Isis Pharmaceuticals, Arbutus Biopharma, Antisense Therapeutics and Alnylam Pharmaceuticals, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Antisense and RNAi Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Antisense and RNAi Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for Antisense and RNAi Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Antisense and RNAi Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Antisense and RNAi Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Antisense and RNAi Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Antisense and RNAi Therapeutics Segment by Company

Roche

Tekmira Pharmaceuticals

Sirnaomics

Silence Therapeutics

Santaris

Isis Pharmaceuticals

Arbutus Biopharma

Antisense Therapeutics

Alnylam Pharmaceuticals

Antisense and RNAi Therapeutics Segment by Type

RNA Interference

Antisense RNA

Antisense and RNAi Therapeutics Segment by Application

Hospital

Clinic

Antisense and RNAi Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antisense and RNAi Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antisense and RNAi Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antisense and RNAi Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Antisense and RNAi Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Antisense and RNAi Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antisense and RNAi Therapeutics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Antisense and RNAi Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. RNA Interference Major Player Table 3. Antisense RNA Major Player Table 4. Global Antisense and RNAi Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Clinic Major Player Table 7. Antisense and RNAi Therapeutics Industry Trends Table 8. Antisense and RNAi Therapeutics Industry Drivers Table 9. Antisense and RNAi Therapeutics Industry Opportunities and Challenges Table 10. Antisense and RNAi Therapeutics Industry Restraints Table 11. Global Antisense and RNAi Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global Antisense and RNAi Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 13. Global Antisense and RNAi Therapeutics Market Share by Region (2021-2026) Table 14. Global Antisense and RNAi Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 15. Global Antisense and RNAi Therapeutics Market Share by Region (2027-2032) Table 16. Global Antisense and RNAi Therapeutics Revenue by Players (US$ Million) & (2021-2026) Table 17. Global Antisense and RNAi Therapeutics Revenue Market Share by Players (2021-2026) Table 18. Global Antisense and RNAi Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global Antisense and RNAi Therapeutics Key Players Headquarters & Area Served Table 20. Global Antisense and RNAi Therapeutics Players, Product Type & Application Table 21. Global Antisense and RNAi Therapeutics Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global Antisense and RNAi Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global Antisense and RNAi Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Antisense and RNAi Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 26. Global Antisense and RNAi Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 27. Global Antisense and RNAi Therapeutics Revenue Market Share by Type (2021-2026) Table 28. Global Antisense and RNAi Therapeutics Revenue Market Share by Type (2027-2032) Table 29. Global Antisense and RNAi Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Antisense and RNAi Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 31. Global Antisense and RNAi Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 32. Global Antisense and RNAi Therapeutics Revenue Market Share by Application (2021-2026) Table 33. Global Antisense and RNAi Therapeutics Revenue Market Share by Application (2027-2032) Table 34. Roche Company Information Table 35. Roche Business Overview Table 36. Roche Antisense and RNAi Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Roche Antisense and RNAi Therapeutics Product Portfolio Table 38. Roche Recent Development Table 39. Tekmira Pharmaceuticals Company Information Table 40. Tekmira Pharmaceuticals Business Overview Table 41. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Product Portfolio Table 43. Tekmira Pharmaceuticals Recent Development Table 44. Sirnaomics Company Information Table 45. Sirnaomics Business Overview Table 46. Sirnaomics Antisense and RNAi Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Sirnaomics Antisense and RNAi Therapeutics Product Portfolio Table 48. Sirnaomics Recent Development Table 49. Silence Therapeutics Company Information Table 50. Silence Therapeutics Business Overview Table 51. Silence Therapeutics Antisense and RNAi Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Silence Therapeutics Antisense and RNAi Therapeutics Product Portfolio Table 53. Silence Therapeutics Recent Development Table 54. Santaris Company Information Table 55. Santaris Business Overview Table 56. Santaris Antisense and RNAi Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Santaris Antisense and RNAi Therapeutics Product Portfolio Table 58. Santaris Recent Development Table 59. Isis Pharmaceuticals Company Information Table 60. Isis Pharmaceuticals Business Overview Table 61. Isis Pharmaceuticals Antisense and RNAi Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Isis Pharmaceuticals Antisense and RNAi Therapeutics Product Portfolio Table 63. Isis Pharmaceuticals Recent Development Table 64. Arbutus Biopharma Company Information Table 65. Arbutus Biopharma Business Overview Table 66. Arbutus Biopharma Antisense and RNAi Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Arbutus Biopharma Antisense and RNAi Therapeutics Product Portfolio Table 68. Arbutus Biopharma Recent Development Table 69. Antisense Therapeutics Company Information Table 70. Antisense Therapeutics Business Overview Table 71. Antisense Therapeutics Antisense and RNAi Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Antisense Therapeutics Antisense and RNAi Therapeutics Product Portfolio Table 73. Antisense Therapeutics Recent Development Table 74. Alnylam Pharmaceuticals Company Information Table 75. Alnylam Pharmaceuticals Business Overview Table 76. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Product Portfolio Table 78. Alnylam Pharmaceuticals Recent Development Table 79. North America Antisense and RNAi Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 80. North America Antisense and RNAi Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 81. North America Antisense and RNAi Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 82. North America Antisense and RNAi Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 83. North America Antisense and RNAi Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 84. North America Antisense and RNAi Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 85. North America Antisense and RNAi Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 86. Europe Antisense and RNAi Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 87. Europe Antisense and RNAi Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 88. Europe Antisense and RNAi Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 89. Europe Antisense and RNAi Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 90. Europe Antisense and RNAi Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 91. Europe Antisense and RNAi Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 92. Europe Antisense and RNAi Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 93. China Antisense and RNAi Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 94. China Antisense and RNAi Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 95. China Antisense and RNAi Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 96. China Antisense and RNAi Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 97. Asia Antisense and RNAi Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 98. Asia Antisense and RNAi Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 99. Asia Antisense and RNAi Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 100. Asia Antisense and RNAi Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 101. Asia Antisense and RNAi Therapeutics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 102. Asia Antisense and RNAi Therapeutics Revenue by Region (US$ Million) & (2021-2026) Table 103. Asia Antisense and RNAi Therapeutics Revenue by Region (US$ Million) & (2027-2032) Table 104. SAMEA Antisense and RNAi Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 105. SAMEA Antisense and RNAi Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 106. SAMEA Antisense and RNAi Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 107. SAMEA Antisense and RNAi Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 108. SAMEA Antisense and RNAi Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 109. SAMEA Antisense and RNAi Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 110. SAMEA Antisense and RNAi Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 111. Research Programs/Design for This Report Table 112. Authors List of This Report Table 113. Secondary Sources Table 114. Primary Sources List of Figures Figure 1. Antisense and RNAi Therapeutics Image Figure 2. Global Antisense and RNAi Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antisense and RNAi Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 4. RNA Interference Image Figure 5. Antisense RNA Image Figure 6. Global Antisense and RNAi Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Antisense and RNAi Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Clinic Image Figure 10. Global Antisense and RNAi Therapeutics Market Size (US$ Million) & (2021-2032) Figure 11. Global Antisense and RNAi Therapeutics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Antisense and RNAi Therapeutics Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global Antisense and RNAi Therapeutics Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global Antisense and RNAi Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Antisense and RNAi Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Antisense and RNAi Therapeutics Revenue Market Share by Type (2021-2032) Figure 18. Global Antisense and RNAi Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Antisense and RNAi Therapeutics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global Antisense and RNAi Therapeutics Revenue Market Share by Application (2021-2032) Figure 21. North America Antisense and RNAi Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Antisense and RNAi Therapeutics Revenue Share by Type (2021-2032) Figure 23. North America Antisense and RNAi Therapeutics Revenue Share by Application (2021-2032) Figure 24. North America Antisense and RNAi Therapeutics Revenue Share by Country (2021-2032) Figure 25. United States Antisense and RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada Antisense and RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico Antisense and RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe Antisense and RNAi Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe Antisense and RNAi Therapeutics Revenue Share by Type (2021-2032) Figure 30. Europe Antisense and RNAi Therapeutics Revenue Share by Application (2021-2032) Figure 31. Europe Antisense and RNAi Therapeutics Revenue Share by Country (2021-2032) Figure 32. Germany Antisense and RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France Antisense and RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. Antisense and RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy Antisense and RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain Antisense and RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia Antisense and RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands Antisense and RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries Antisense and RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China Antisense and RNAi Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China Antisense and RNAi Therapeutics Revenue Share by Type (2021-2032) Figure 42. China Antisense and RNAi Therapeutics Revenue Share by Application (2021-2032) Figure 43. Asia Antisense and RNAi Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia Antisense and RNAi Therapeutics Revenue Share by Type (2021-2032) Figure 45. Asia Antisense and RNAi Therapeutics Revenue Share by Application (2021-2032) Figure 46. Asia Antisense and RNAi Therapeutics Revenue Share by Region (2021-2032) Figure 47. Japan Antisense and RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea Antisense and RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India Antisense and RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia Antisense and RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan Antisense and RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia Antisense and RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA Antisense and RNAi Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA Antisense and RNAi Therapeutics Revenue Share by Type (2021-2032) Figure 55. SAMEA Antisense and RNAi Therapeutics Revenue Share by Application (2021-2032) Figure 56. SAMEA Antisense and RNAi Therapeutics Revenue Share by Country (2021-2032) Figure 57. Brazil Antisense and RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina Antisense and RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile Antisense and RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia Antisense and RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru Antisense and RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia Antisense and RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel Antisense and RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE Antisense and RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey Antisense and RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran Antisense and RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt Antisense and RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • RNA Interference
  • Antisense RNA
Applications
  • Hospital
  • Clinic
Companies covered
  • Roche
  • Tekmira Pharmaceuticals
  • Sirnaomics
  • Silence Therapeutics
  • Santaris
  • Isis Pharmaceuticals
  • Arbutus Biopharma
  • Antisense Therapeutics
  • Alnylam Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Antisense and RNAi Therapeutics Market by Type
  3. 1.2.1 Global Antisense and RNAi Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 RNA Interference
  5. 1.2.3 Antisense RNA
  6. 1.3 Antisense and RNAi Therapeutics Market by Application
  7. 1.3.1 Global Antisense and RNAi Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Clinic
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Antisense and RNAi Therapeutics Market Dynamics
  1. 2.1 Antisense and RNAi Therapeutics Industry Trends
  2. 2.2 Antisense and RNAi Therapeutics Industry Drivers
  3. 2.3 Antisense and RNAi Therapeutics Industry Opportunities and Challenges
  4. 2.4 Antisense and RNAi Therapeutics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Antisense and RNAi Therapeutics Market Perspective (2021-2032)
  2. 3.2 Global Antisense and RNAi Therapeutics Growth Trends by Region
  3. 3.2.1 Global Antisense and RNAi Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Antisense and RNAi Therapeutics Market Size by Region (2021-2026)
  5. 3.2.3 Global Antisense and RNAi Therapeutics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Antisense and RNAi Therapeutics Revenue by Players
  2. 4.1.1 Global Antisense and RNAi Therapeutics Revenue by Players (2021-2026)
  3. 4.1.2 Global Antisense and RNAi Therapeutics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Antisense and RNAi Therapeutics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Antisense and RNAi Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Antisense and RNAi Therapeutics Key Players Headquarters & Area Served
  7. 4.4 Global Antisense and RNAi Therapeutics Players, Product Type & Application
  8. 4.5 Global Antisense and RNAi Therapeutics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Antisense and RNAi Therapeutics Market CR5 and HHI
  11. 4.6.3 2025 Antisense and RNAi Therapeutics Tier 1, Tier 2, and Tier 3
5 Antisense and RNAi Therapeutics Market Size by Type
  1. 5.1 Global Antisense and RNAi Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Antisense and RNAi Therapeutics Revenue by Type (2021-2032)
  3. 5.3 Global Antisense and RNAi Therapeutics Revenue Market Share by Type (2021-2032)
6 Antisense and RNAi Therapeutics Market Size by Application
  1. 6.1 Global Antisense and RNAi Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Antisense and RNAi Therapeutics Revenue by Application (2021-2032)
  3. 6.3 Global Antisense and RNAi Therapeutics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Roche
  2. 7.1.1 Roche Company Information
  3. 7.1.2 Roche Business Overview
  4. 7.1.3 Roche Antisense and RNAi Therapeutics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Roche Antisense and RNAi Therapeutics Product Portfolio
  6. 7.1.5 Roche Recent Developments
  7. 7.2 Tekmira Pharmaceuticals
  8. 7.2.1 Tekmira Pharmaceuticals Company Information
  9. 7.2.2 Tekmira Pharmaceuticals Business Overview
  10. 7.2.3 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Product Portfolio
  12. 7.2.5 Tekmira Pharmaceuticals Recent Developments
  13. 7.3 Sirnaomics
  14. 7.3.1 Sirnaomics Company Information
  15. 7.3.2 Sirnaomics Business Overview
  16. 7.3.3 Sirnaomics Antisense and RNAi Therapeutics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Sirnaomics Antisense and RNAi Therapeutics Product Portfolio
  18. 7.3.5 Sirnaomics Recent Developments
  19. 7.4 Silence Therapeutics
  20. 7.4.1 Silence Therapeutics Company Information
  21. 7.4.2 Silence Therapeutics Business Overview
  22. 7.4.3 Silence Therapeutics Antisense and RNAi Therapeutics Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Silence Therapeutics Antisense and RNAi Therapeutics Product Portfolio
  24. 7.4.5 Silence Therapeutics Recent Developments
  25. 7.5 Santaris
  26. 7.5.1 Santaris Company Information
  27. 7.5.2 Santaris Business Overview
  28. 7.5.3 Santaris Antisense and RNAi Therapeutics Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Santaris Antisense and RNAi Therapeutics Product Portfolio
  30. 7.5.5 Santaris Recent Developments
  31. 7.6 Isis Pharmaceuticals
  32. 7.6.1 Isis Pharmaceuticals Company Information
  33. 7.6.2 Isis Pharmaceuticals Business Overview
  34. 7.6.3 Isis Pharmaceuticals Antisense and RNAi Therapeutics Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Isis Pharmaceuticals Antisense and RNAi Therapeutics Product Portfolio
  36. 7.6.5 Isis Pharmaceuticals Recent Developments
  37. 7.7 Arbutus Biopharma
  38. 7.7.1 Arbutus Biopharma Company Information
  39. 7.7.2 Arbutus Biopharma Business Overview
  40. 7.7.3 Arbutus Biopharma Antisense and RNAi Therapeutics Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Arbutus Biopharma Antisense and RNAi Therapeutics Product Portfolio
  42. 7.7.5 Arbutus Biopharma Recent Developments
  43. 7.8 Antisense Therapeutics
  44. 7.8.1 Antisense Therapeutics Company Information
  45. 7.8.2 Antisense Therapeutics Business Overview
  46. 7.8.3 Antisense Therapeutics Antisense and RNAi Therapeutics Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Antisense Therapeutics Antisense and RNAi Therapeutics Product Portfolio
  48. 7.8.5 Antisense Therapeutics Recent Developments
  49. 7.9 Alnylam Pharmaceuticals
  50. 7.9.1 Alnylam Pharmaceuticals Company Information
  51. 7.9.2 Alnylam Pharmaceuticals Business Overview
  52. 7.9.3 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Product Portfolio
  54. 7.9.5 Alnylam Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Antisense and RNAi Therapeutics Revenue (2021-2032)
  2. 8.2 North America Antisense and RNAi Therapeutics Revenue by Type (2021-2032)
  3. 8.2.1 North America Antisense and RNAi Therapeutics Revenue by Type (2021-2026)
  4. 8.2.2 North America Antisense and RNAi Therapeutics Revenue by Type (2027-2032)
  5. 8.3 North America Antisense and RNAi Therapeutics Revenue Share by Type (2021-2032)
  6. 8.4 North America Antisense and RNAi Therapeutics Revenue by Application (2021-2032)
  7. 8.4.1 North America Antisense and RNAi Therapeutics Revenue by Application (2021-2026)
  8. 8.4.2 North America Antisense and RNAi Therapeutics Revenue by Application (2027-2032)
  9. 8.5 North America Antisense and RNAi Therapeutics Revenue Share by Application (2021-2032)
  10. 8.6 North America Antisense and RNAi Therapeutics Revenue by Country
  11. 8.6.1 North America Antisense and RNAi Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Antisense and RNAi Therapeutics Revenue by Country (2021-2026)
  13. 8.6.3 North America Antisense and RNAi Therapeutics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Antisense and RNAi Therapeutics Revenue (2021-2032)
  2. 9.2 Europe Antisense and RNAi Therapeutics Revenue by Type (2021-2032)
  3. 9.2.1 Europe Antisense and RNAi Therapeutics Revenue by Type (2021-2026)
  4. 9.2.2 Europe Antisense and RNAi Therapeutics Revenue by Type (2027-2032)
  5. 9.3 Europe Antisense and RNAi Therapeutics Revenue Share by Type (2021-2032)
  6. 9.4 Europe Antisense and RNAi Therapeutics Revenue by Application (2021-2032)
  7. 9.4.1 Europe Antisense and RNAi Therapeutics Revenue by Application (2021-2026)
  8. 9.4.2 Europe Antisense and RNAi Therapeutics Revenue by Application (2027-2032)
  9. 9.5 Europe Antisense and RNAi Therapeutics Revenue Share by Application (2021-2032)
  10. 9.6 Europe Antisense and RNAi Therapeutics Revenue by Country
  11. 9.6.1 Europe Antisense and RNAi Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Antisense and RNAi Therapeutics Revenue by Country (2021-2026)
  13. 9.6.3 Europe Antisense and RNAi Therapeutics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Antisense and RNAi Therapeutics Revenue (2021-2032)
  2. 10.2 China Antisense and RNAi Therapeutics Revenue by Type (2021-2032)
  3. 10.2.1 China Antisense and RNAi Therapeutics Revenue by Type (2021-2026)
  4. 10.2.2 China Antisense and RNAi Therapeutics Revenue by Type (2027-2032)
  5. 10.3 China Antisense and RNAi Therapeutics Revenue Share by Type (2021-2032)
  6. 10.4 China Antisense and RNAi Therapeutics Revenue by Application (2021-2032)
  7. 10.4.1 China Antisense and RNAi Therapeutics Revenue by Application (2021-2026)
  8. 10.4.2 China Antisense and RNAi Therapeutics Revenue by Application (2027-2032)
  9. 10.5 China Antisense and RNAi Therapeutics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Antisense and RNAi Therapeutics Revenue (2021-2032)
  2. 11.2 Asia Antisense and RNAi Therapeutics Revenue by Type (2021-2032)
  3. 11.2.1 Asia Antisense and RNAi Therapeutics Revenue by Type (2021-2026)
  4. 11.2.2 Asia Antisense and RNAi Therapeutics Revenue by Type (2027-2032)
  5. 11.3 Asia Antisense and RNAi Therapeutics Revenue Share by Type (2021-2032)
  6. 11.4 Asia Antisense and RNAi Therapeutics Revenue by Application (2021-2032)
  7. 11.4.1 Asia Antisense and RNAi Therapeutics Revenue by Application (2021-2026)
  8. 11.4.2 Asia Antisense and RNAi Therapeutics Revenue by Application (2027-2032)
  9. 11.5 Asia Antisense and RNAi Therapeutics Revenue Share by Application (2021-2032)
  10. 11.6 Asia Antisense and RNAi Therapeutics Revenue by Country
  11. 11.6.1 Asia Antisense and RNAi Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Antisense and RNAi Therapeutics Revenue by Country (2021-2026)
  13. 11.6.3 Asia Antisense and RNAi Therapeutics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Antisense and RNAi Therapeutics Revenue (2021-2032)
  2. 12.2 SAMEA Antisense and RNAi Therapeutics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Antisense and RNAi Therapeutics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Antisense and RNAi Therapeutics Revenue by Type (2027-2032)
  5. 12.3 SAMEA Antisense and RNAi Therapeutics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Antisense and RNAi Therapeutics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Antisense and RNAi Therapeutics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Antisense and RNAi Therapeutics Revenue by Application (2027-2032)
  9. 12.5 SAMEA Antisense and RNAi Therapeutics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Antisense and RNAi Therapeutics Revenue by Country
  11. 12.6.1 SAMEA Antisense and RNAi Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Antisense and RNAi Therapeutics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Antisense and RNAi Therapeutics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst